We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge Invalidates Ampyra Patents, Clearing Path for Generics a Decade Early
Judge Invalidates Ampyra Patents, Clearing Path for Generics a Decade Early
Four major patents for Acorda Therapeutics’ successful MS treatment Ampyra were invalidated by a federal judge nearly a decade before they were set to expire — less than a month after they were upheld by the PTO.